Research article · 19 Aug 2025
Conference abstractPublished 3 Jul 2017
Crocin-coated magnetite nanoparticles: A potential therapeutic alternative against liver cancer
United Arab Emirates University, UAE
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The aim of this study was to develop an effective method for treatment of liver cancer using magnetite nanoparticles (MNPs) coated with crocin, the main active component of saffron. MNPs were coated with dextran and a cross-linker to enhance conjugation of crocin. Treatment of HepG2 cells with crocin-coated MNPs led to a significant inhibition of their growth as compared to control or those treated with free crocin or uncoated MNPs. Histological examinations of the livers of cancer-induced mice revealed several precancerous changes such as multiple proliferative hepatic foci, hyper- or dysplastic transformations of bile ducts/ductules and vacuolation. Immunohistochemistry using antibodies specific for cell proliferation (Ki-67) and apoptosis (M30-CytoDEATH and Bcl-2) revealed their up-regulation during development of precancerous lesions. Using antibodies specific for inflammation (cyclooxygenase-2), oxidative stress (glutathione) and angiogenesis (vascular endothelial growth factor) indicated the involvement of multiple signaling pathways in the development of precancerous lesions. Treatment with crocin-coated MNPs was associated with regression of precancerous lesions, significant up-regulation of apoptotic cells and down-regulation of Bcl-2 labeling and markers of cell proliferation, inflammation, oxidative stress and angiogenesis. In conclusion, crocin-coated MNPs are more effective than free crocin for treatment of liver precancerous lesions in mice. These findings will help to develop new modalities for early detection and treatment of liver precancerous lesions.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Drug Designing: Open Access.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalDrug Designing: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Amr Amin”
- BylineArticles whose byline prints “Rkia El-Kharrag”
- BylineArticles whose byline prints “Soleiman Hisaindee”
- BylineArticles whose byline prints “Yaser Greish”
- BylineArticles whose byline prints “Sherif M Karam”
